About Edgewise Therapeutics, Inc.
https://www.edgewisetx.comEdgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
CEO
Kevin Koch
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 115
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
RBC Capital
Outperform
Wedbush
Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Scotiabank
Sector Perform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:15.52M
Value:$437.16M
RA CAPITAL MANAGEMENT, L.P.
Shares:10.43M
Value:$293.77M
BAKER BROS. ADVISORS LP
Shares:7.31M
Value:$205.81M
Summary
Showing Top 3 of 188
About Edgewise Therapeutics, Inc.
https://www.edgewisetx.comEdgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $46.86M ▲ | $-40.67M ▼ | 0% | $-0.39 ▼ | $-40.14M ▲ |
| Q2-2025 | $0 | $42.61M ▼ | $-36.12M ▲ | 0% | $-0.34 ▲ | $-42.04M ▲ |
| Q1-2025 | $0 | $45.96M ▲ | $-40.8M ▼ | 0% | $-0.43 ▼ | $-45.41M ▼ |
| Q4-2024 | $0 | $45.54M ▲ | $-39.66M ▼ | 0% | $-0.42 ▼ | $-44.91M ▼ |
| Q3-2024 | $0 | $40.43M | $-34.13M | 0% | $-0.36 | $-39.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $563.34M ▼ | $583.47M ▼ | $24.82M ▲ | $558.65M ▼ |
| Q2-2025 | $593.99M ▲ | $613.33M ▲ | $24.26M ▼ | $589.07M ▲ |
| Q1-2025 | $436.39M ▼ | $454.39M ▼ | $24.67M ▼ | $429.72M ▼ |
| Q4-2024 | $470.17M ▼ | $486.82M ▼ | $27.6M ▲ | $459.22M ▼ |
| Q3-2024 | $492.54M | $511.28M | $22.41M | $488.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-40.67M ▼ | $-34.78M ▼ | $35.72M ▲ | $1.66M ▼ | $2.6M ▲ | $-34.87M ▼ |
| Q2-2025 | $-36.12M ▲ | $-32.58M ▲ | $-162.17M ▼ | $188.23M ▲ | $-6.52M ▼ | $-32.63M ▲ |
| Q1-2025 | $-40.8M ▼ | $-37.87M ▼ | $43.9M ▲ | $2.22M ▼ | $8.26M ▲ | $-37.91M ▼ |
| Q4-2024 | $-39.66M ▼ | $-26.96M ▲ | $20.92M ▼ | $2.9M ▼ | $-3.14M ▼ | $-27.23M ▲ |
| Q3-2024 | $-34.13M | $-27.37M | $25.36M | $3.33M | $1.32M | $-27.89M |
CEO
Kevin Koch
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 115
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
RBC Capital
Outperform
Wedbush
Outperform
JP Morgan
Overweight
Piper Sandler
Overweight
Scotiabank
Sector Perform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:15.52M
Value:$437.16M
RA CAPITAL MANAGEMENT, L.P.
Shares:10.43M
Value:$293.77M
BAKER BROS. ADVISORS LP
Shares:7.31M
Value:$205.81M
Summary
Showing Top 3 of 188